大洋生物(003017) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥194,843,722.18, a decrease of 22.46% compared to ¥251,292,978.42 in the same period last year[5] - Net profit attributable to shareholders was ¥16,918,222.12, down 12.78% from ¥19,396,982.24 year-on-year[5] - Basic and diluted earnings per share decreased by 38.24% to ¥0.21 from ¥0.34 in the same period last year[5] - Total operating revenue for Q1 2024 was CNY 194,843,722.18, a decrease of 22.4% compared to CNY 251,292,978.42 in Q1 2023[24] - Net profit for Q1 2024 was CNY 16,918,222.12, a decline of 12.7% from CNY 19,396,982.24 in Q1 2023[26] - Basic and diluted earnings per share for Q1 2024 were CNY 0.21, compared to CNY 0.34 in Q1 2023[26] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥176,291.06, compared to a negative cash flow of ¥22,210,464.08 in the previous year, marking a 100.79% increase[5] - The cash flow from operating activities for Q1 2024 was CNY 176,291.06, a significant improvement from a negative cash flow of CNY -22,210,464.08 in the same period last year[28] - Total cash inflow from operating activities was CNY 177,121,488.87, down 5.4% from CNY 188,109,351.42 in Q1 2023[28] - Cash outflow from operating activities totaled CNY 176,945,197.81, a decrease of 15.8% compared to CNY 210,319,815.50 in the previous year[28] - The net cash flow from financing activities was -¥55,746,748.63, a decrease of 243.73% due to increased debt repayments and share buyback payments[11] - The net cash flow from financing activities was CNY -55,746,748.63, compared to a positive cash flow of CNY 38,786,348.38 in Q1 2023[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,485,751,171.04, down 3.94% from ¥1,546,672,439.50 at the end of the previous year[5] - Total liabilities decreased to CNY 494,864,346.38 in Q1 2024 from CNY 538,465,015.51 in Q1 2023, reflecting a reduction of 8.1%[22] - The company's total current assets decreased to RMB 591,630,282.86 from RMB 661,633,569.19, a decline of approximately 10.5%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,881[13] - The top 10 shareholders hold a combined 25.67% of the shares, with the largest shareholder, Chen Yanggui, owning 8.86%[13] Operational Highlights - The company reported a significant increase in accounts receivable by 73.31%, reaching ¥66,610,239.58, attributed to higher shipment volumes at the quarter's end[10] - Inventory at the end of the reporting period was RMB 163,287,180.82, up from RMB 152,230,263.34, an increase of about 7.0%[19] - Research and development expenses for Q1 2024 were CNY 6,625,360.56, a decrease of 22.0% from CNY 8,499,851.91 in Q1 2023, suggesting a potential shift in focus or cost management[24] Corporate Developments - The company appointed Chen Xujun as the new general manager, effective from January 26, 2024[15] - The company received a high-tech enterprise certificate valid for three years, enhancing its innovation capabilities[15] - The company plans to repurchase shares at a price not exceeding RMB 28.00 per share, with a total repurchase amount expected to be no less than RMB 42 million and not exceeding RMB 84 million[16][17] Tax and Other Income - The company recorded a 74.47% increase in other income, amounting to ¥5,464,468.02, due to tax incentives for advanced manufacturing enterprises[11] - The company received CNY 3,487,552.55 in tax refunds during the quarter, down from CNY 4,918,228.44 in the previous year[28] - The total cash outflow for taxes paid was CNY 9,865,177.96, a decrease of 59.0% from CNY 24,091,719.18 in Q1 2023[28]